New research advances on AKIR001 to be presented at EANM Congress 2024

Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, will participate in the European Association of Nuclear Medicine (EANM) Congress 2024 in Hamburg, from October 19-23. At this year’s congress, research findings on Akiram's drug candidate AKIR001, resulting from several successful academic collaborations, will be presented.

Akiram Therapeutics has developed ¹⁷⁷Lu-AKIR001, a new type of targeted radioimmunotherapy. The therapy holds the potential to become a first-in-class treatment in multiple cancer types, including anaplastic and iodine-refractory thyroid cancer, head and neck squamous cell carcinoma, and non-small cell lung cancer. The drug is composed of a target recognition molecule to which therapeutic radioactivity is coupled for effect on tumor cells.

The presentations at the EANM Congress will focus on the development and optimization of the drug in preparation for upcoming clinical trials. Specifically, the cGMP production process, which ensures the drug can be manufactured according to high-quality standards for clinical studies, will be highlighted.

The presentation on the cGMP development of ¹⁷⁷Lu-AKIR001 has been selected as one of the Top-Rated Oral Presentations at the congress:

Title: cGMP development of the ¹⁷⁷Lu-AKIR001 for clinical translation in first-in-human studies of CD44v6 expressing cancer patients
Presentation No.: OP-082
Date & Time: October 20, 9:45 AM, Hall X1-X4
Speaker: Klas Bratteby

Additionally, several other key research findings on ¹⁷⁷Lu-AKIR001 will be showcased as posters, including:

• ¹⁷⁷Lu-AKIR001 inhibits growth of pancreatic tumour xenografts
  Poster No.: EP-0100
  Presented by: Amanda Gustafsson
• Fractionation of ¹⁷⁷Lu-DOTA-AKIR001 results in increased curative rates and favorable hematopoietic toxicities compared to single high dose
  Poster No.:EP-0992
  Presented by: Anja Mortensen
• Biodistribution and in vivo efficacy of ¹⁶¹Tb-labeled AKIR001, a novel anti-CD44v6 antibody
  Poster No.: EP-0991
  Presented by: Anja Mortensen

“We are thrilled to see the results of our academic collaborations presented at the EANM Congress. ¹⁷⁷Lu-AKIR001 has shown great preclinical potential to transform the treatment of CD44v6-expressing tumors. We are looking forward to starting phase 1 studies later this fall, with the goal of offering new, targeted treatment options for patients with hard-to-treat cancers,” says Marika Nestor, CEO of Akiram Therapeutics. “The selection of the cGMP production presentation as one of the top-rated talks is a clear recognition of the promising research, and we are excited to share the results with the international scientific community.”

EANM – The European Association of Nuclear Medicine
The annual EANM Congress is one of the premier global platforms where leading experts and industry representatives from around the world gather to discuss advancements and future trends in nuclear medicine. Read more: https://eanm24.eanm.org/

About Akiram’s Drug Candidate
Developed through antibody phage display and affinity maturation targeting the CD44v6 cancer marker, ¹⁷⁷Lu-AKIR001 combines the radiation component lutetium-177 with a targeted molecule. Preclinical studies have demonstrated its potential as a promising, first-in-class radiopharmaceutical therapy for cancers with high CD44v6 expression.

For more information, please contact:
Marika Nestor, CEO
Email: marika.nestor@akiramtherapeutics.com

About Akiram Therapeutics
Akiram Therapeutics is a Swedish biotech company focused on the development of targeted radioimmunotherapy for cancer, which is based on a proprietary antibody targeting the cancer marker CD44v6 combined with a radiation component. The therapy has generated strong preclinical results in cancer models in conditions that currently lack effective treatments. With the potential for its drug candidate to be classified as an orphan drug and recognized as first-in-class, the company is dedicated to advancing research in this field, including indications in head and neck cancer, lung cancer, and aggressive thyroid cancer. Headquartered in Uppsala, Sweden, Akiram Therapeutics is staffed with experts in radiation science research, cancer precision medicine, and drug development. To learn more, please visit Akiram’s website and follow Akiram on LinkedIn.

Tags: